Phase II Trial of LBH589 in Refractory Colorectal Cancer
The purpose of this study is to determine the effects of the study drug, LBH589, on patients with metastatic colorectal cancer that has continued to grow despite previous treatment.
Colorectal Cancer
DRUG: LBH589
To evaluate the effect of LBH589 on overall survival (OS) in patients with colorectal cancer, 18 months
Time to tumor progression and response rates, 18 months
The purpose of this study is to determine the effects of the study drug, LBH589, on patients with metastatic colorectal cancer that has continued to grow despite previous treatment.